ZyVersa Therapeutics, Inc.
ZVSA
$0.6794
-$0.0306-4.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 20.16% | 89.34% | 17.27% | 96.48% | 20.24% |
| Total Depreciation and Amortization | -- | 93.13% | -98.57% | 300.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.45% | -97.65% | 7.64% | -99.78% | 190.74% |
| Change in Net Operating Assets | 126.21% | 94.41% | -6.10% | -77.50% | -78.96% |
| Cash from Operations | 53.08% | 56.07% | 31.18% | -369.60% | 17.71% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -25.17% | -39.19% | -73.00% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 37.58% | 67.25% | -- | -- |
| Cash from Financing | -30.68% | -39.43% | -71.67% | 100.00% | 7,801.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.30% | -9.69% | -99.75% | -82.40% | 76.12% |